Welcome to our dedicated page for Dermata Therapeutics SEC filings (Ticker: DRMA), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Spongilla microparticles, Phase 3 endpoints, and cash-runway disclosures: Dermata Therapeutics’ SEC filings pack dense biotechnology jargon into hundreds of pages. Finding where the 10-K discusses trial dropout rates or which Form 4 signals insider confidence can feel impossible.
Stock Titan solves this. Our AI reads every Dermata Therapeutics annual report 10-K simplified and each Dermata Therapeutics quarterly earnings report 10-Q filing, surfacing the R&D spend, patent expirations, and liquidity tables in plain English. Need fast alerts on Dermata Therapeutics Form 4 insider transactions real-time? We deliver them within seconds, flagging notable buys and sells. Curious about adverse-event disclosures? The platform links the exact line in the latest Dermata Therapeutics 8-K material events explained. It even answers natural questions like “Why did R&D jump this quarter?”—that’s understanding Dermata Therapeutics SEC documents with AI.
Whether you’re screening Dermata Therapeutics executive stock transactions Form 4, comparing segment costs across filings, or reviewing the Dermata Therapeutics proxy statement executive compensation, you’ll find it all here. Real-time updates from EDGAR ensure Dermata Therapeutics insider trading Form 4 transactions appear alongside our concise notes. Built-in charts provide Dermata Therapeutics earnings report filing analysis so you can track trial-driven revenue potential without wading through PDFs. Stop searching, start analyzing—every Dermata document, every insight, already distilled.
Dermata Therapeutics, Inc. has filed a replacement shelf registration statement allowing it to offer up to $100,000,000 of common stock, preferred stock, warrants, debt securities, subscription rights and units from time to time. This base shelf, filed under Rule 415(a)(6), refreshes unsold securities from a prior registration and preserves the company’s ability to raise capital as needed. As of November 21, 2025, Dermata had 1,026,457 shares of common stock outstanding and a public float of 910,575 shares valued at $2,258,226 based on a $2.48 share price. The company is pivoting from prescription dermatology to over-the-counter, science-backed skin-care products built on its Spongilla technology, targeting acne and other common skin conditions, with an initial once-weekly topical acne kit expected to launch in mid‑2026. Dermata remains pre‑revenue, reported net losses of $5.7 million for the nine months ended September 30, 2025, and plans to use any proceeds primarily for working capital and general corporate purposes.
Dermata Therapeutics, Inc. announced that it has elected to terminate its License Agreement with Villani, Inc., with the termination becoming effective 90 days after Villani receives the notice. This move is tied to Dermata’s recent strategic shift toward commercializing over-the-counter skin care treatments and its withdrawal of the XYNGARI™ investigational new drug application with the U.S. Food and Drug Administration.
Under the original agreement, Villani had granted Dermata an exclusive, sub-licensable, royalty-bearing license to develop and sell sponge-based pharmaceutical products for skin diseases and conditions. Dermata had agreed to pay up to $40.5 million in future development and sales milestone payments, plus single-digit royalties on net sales. After the termination date, Villani will not receive further milestone or other payments, Dermata’s development and commercialization obligations for licensed products will end, and the Villani licenses will cease to be in effect.
Dermata Therapeutics (DRMA) filed its Q3 2025 report, showing lower losses and a strategic pivot to over-the-counter (OTC) dermatology products. Net loss was $1.69 million for the quarter, improving from $3.17 million a year ago, as research and development fell to $0.50 million with its Phase 3 STAR-1 trial completed. Selling, general and administrative expense rose to $1.26 million, including $0.33 million of related party amounts tied to branding and launch preparation.
Cash and cash equivalents were $4.66 million as of September 30, 2025, with total liabilities of $1.11 million and stockholders’ equity of $3.96 million. The company expects its cash to fund operations into the second quarter of 2026 and disclosed substantial doubt about its ability to continue as a going concern. Management plans to launch its first OTC product candidate in mid-2026. Capital raised year-to-date included approximately $5.7 million from a March 2025 warrant inducement and approximately $2.2 million net from a January 2025 PIPE. A 1‑for‑10 reverse stock split became effective August 1, 2025. Shares outstanding were 1,026,457 as of November 12, 2025.
Dermata Therapeutics, Inc. furnished an 8-K announcing a press release with a corporate update and financial results for the quarter ended September 30, 2025. The press release is attached as Exhibit 99.1, titled “Dermata Therapeutics Provides Corporate Update and Reports Third Quarter 2025 Financial Results.”
The information under Item 2.02 and Exhibit 99.1 is furnished, not deemed filed under Section 18 of the Exchange Act, and is not incorporated by reference unless expressly stated.
Dermata Therapeutics filed an 8-K announcing it has filed a prospectus supplement to increase the maximum aggregate offering amount of common stock issuable under its At The Market Offering Agreement with H.C. Wainwright & Co., LLC by $1,792,315.
The company previously sold $1,662,142 of common stock under this agreement pursuant to a prior prospectus supplement. The filing also includes a legal opinion covering the additional $1,792,315 of shares tied to the Current Prospectus Supplement.
Dermata Therapeutics (DRMA) filed a prospectus supplement for its at-the-market program, permitting sales of up to $1,792,315 of common stock through H.C. Wainwright & Co. under its effective S-3, subject to General Instruction I.B.6 limitations.
This cap reflects a public float of approximately $5,376,945, calculated on 910,575 non‑affiliate shares at $5.905 as of September 16, 2025. The amount does not include approximately $1,662,142 previously sold under earlier supplements. Any additional sales capacity will be addressed in a subsequent supplement.
DRMA’s common stock trades on Nasdaq under “DRMA”; the last reported sale price was $2.95 on November 6, 2025. The company is an emerging growth company and smaller reporting company.
FAQ
What is the current stock price of Dermata Therapeutics (DRMA)?
What is the market cap of Dermata Therapeutics (DRMA)?
